Zelluna Asa Is A Biotechnology Company Dedicated To Developing Innovative Cell Therapies For Cancer Treatmentwith A Focus On Advanced Solid Tumorsfounded In 2016 And Publicly Listed On The Oslo Stock Exchangezelluna Aims To Eliminate Solid Cancers By Utilizing Components Of The Immune Systemthe Company Is Led By Experienced Biotech Entrepreneurs In Immune Oncology Zelluna Specializes In T Cell Receptor Guided Natural Killertcr Nkcell Therapiesdesigned Asoff The Shelftreatments To Enhance Scalabilitytheir Proprietary Platform Targets Cancer Specific Antigensharnesses The Potency Of Natural Killer Cellsand Employs Automated Manufacturing Processes For Efficient Productionthe Lead Candidatezi Ma4 1Targets Mage A4 For Solid Tumors And Is Preparing For Clinical Trials In Late 2025Zelluna S Mission Is To Provide Safe And Accessible Treatments For Advanced Solid Cancersemphasizing Partnerships With Clinical Institutions And Cdmos To Support Their Innovative Therapies
No conferences found for this company.
| Company Name | Ultimovacs As |
| Country |
Norway
|
| Address | N/A |
| Telephone | N/A |
| N/A |
